News coverage about Zogenix (NASDAQ:ZGNX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zogenix earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.34667777446 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern’s scoring:
- Zogenix’s (ZGNX) Buy Rating Reaffirmed at Mizuho (americanbankingnews.com)
- Employee Stock Options Liability Significant For Zogenix (finance.yahoo.com)
- Q1 2018 EPS Estimates for Zogenix, Inc. (ZGNX) Raised by Analyst (americanbankingnews.com)
- Zogenix, Inc. (ZGNX) Expected to Earn Q1 2018 Earnings of ($0.78) Per Share (americanbankingnews.com)
- Zogenix, Inc. (ZGNX) Forecasted to Earn Q1 2019 Earnings of ($0.91) Per Share (americanbankingnews.com)
Shares of Zogenix (NASDAQ:ZGNX) traded down $0.10 during midday trading on Wednesday, reaching $44.40. The company’s stock had a trading volume of 89,399 shares, compared to its average volume of 599,773. Zogenix has a fifty-two week low of $10.00 and a fifty-two week high of $45.85. The firm has a market capitalization of $1,530.00, a P/E ratio of -12.63 and a beta of 1.57.
Several research firms have recently issued reports on ZGNX. Mizuho reaffirmed a “buy” rating and issued a $51.00 price target on shares of Zogenix in a research report on Wednesday, March 7th. BidaskClub lowered shares of Zogenix from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Leerink Swann reiterated an “outperform” rating on shares of Zogenix in a research note on Sunday, March 4th. JMP Securities initiated coverage on Zogenix in a research note on Monday, November 27th. They set an “outperform” rating and a $56.00 price objective for the company. Finally, Zacks Investment Research upgraded Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, January 27th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Zogenix currently has a consensus rating of “Buy” and a consensus target price of $46.40.
TRADEMARK VIOLATION WARNING: This piece was published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/2018/03/14/zogenix-zgnx-getting-somewhat-favorable-media-coverage-study-shows/1972926.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.